Pyrropyrimidine compounds as mnks inhibitors

Abstract

The present invention relates to compounds of formulae I, or pharmaceutically acceptable salts or esters thereof, wherein: Ris selected from H and CO—NRR, wherein Rand Rare each independently selected from H, alkyl, cycloalkyl and mono or bicyclic heterocycloalkyl, wherein said alkyl group is optionally substituted by one or more Rgroups, and said heterocycloalkyl is optionally substituted by Ror R; or Rand Rare linked, together with the nitrogen to which they are attached, to form a heterocycloalkyl group optionally containing one or more additional heteroatoms, and optionally substituted by one or more groups select from Rand (CH)R; Ris selected from H and alkyl, wherein said alkyl group is optionally substituted by one or more Rgroups; Ris selected from alkyl, cycloalkyl and heterocycloalkyl, each of which may be optionally substituted by halo, OH or alkoxy; Z, Z, Zand Zare all C; R, R, Rand Rare each independently selected from H, alkyl, CN, NO, OH, alkoxy, NHCO-alkyl, halo and haloalkyl; or Z, Zand Zare all C, Zis N, Ris absent and R, Rand Rare as defined above; or Z, Zand Zare all C, Zis N, Ris absent and R, Rand Rare as defined above; each Rand R11 is independently alkyl; each Ris independently selected from COR, COOH, OH, alkoxy, haloalkyl, NH, NHR, NRR, heteroaryl and heterocycloalkyl; Ris H or halo. Further aspects relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.